Introduction Many serious drug adverse events (AEs) only manifest well after regulatory approval. Therefore, the development of signaling methods to use with post-approval AE databases appears vital to comprehensively assess real-world drug safety. However, with millions of potential drug-AE pairs to analyze, the issue of focus is daunting. Objective Our objective was to develop a signaling platform that focuses on AEs with historically demonstrated regulatory interest and to analyze such AEs with a disproportional reporting method that offers broad signal detection and acceptable false-positive rates. Methods We analyzed over 1500 US FDA regulatory actions (safety communications and drug label changes) from 2008 to 2015 to construct a list of eligible signal AEs. The FDA Adverse Event Reporting System (FAERS) was used to evaluate disproportional reporting rates, constrained by minimum case counts and confidence interval limits, of these selected AEs for 109 training drugs. This step led to 45 AEs that appeared to have a low likelihood of being added to a label by FDA, so they were removed from the signal eligible list. We measured disproportional reporting for the final group of eligible AEs on a test group of 29 drugs that were not used in either the eligible list construction or the training steps. Results In a group of 29 test drugs, our model reduced the number of potential drug-AE signals from 41,834 to 97 and predicted 73 % of individual drug label changes. The model also predicted at least one AE-drug pair label change in 66 % of all the label changes for the test drugs. Conclusions By concentrating on AE types with already demonstrated interest to FDA, we constructed a signaling system that provided focus regarding drug-AE pairs and suitable accuracy with regard to the issuance of FDA labeling changes. We suggest that focus on historical regulatory actions may increase the utility of pharmacovigilance signaling systems.
Introduction
It is a widely accepted concept that pre-approval drug clinical trial programs often fail to uncover serious and lifethreatening side effects. In fact, many adverse events (AEs) only become evident well after a regulatory body has approved a drug [1] [2] [3] [4] .
Drug-prescribing information documents ('labels' or 'inserts') are widely used sources of safety information for the healthcare industry. In theory, this information is supposed to provide comprehensive and continually updated information regarding AEs potentially associated with the use of a given prescription drug. However, in practice, discrepancies occur between safety data disclosed in label inserts and side effects that occur in the real world because (1) there is often a significant discrepancy between AEs observed in clinical trials compared with those reported in corresponding publications on the same trials [5] [6] [7] , and (2) publication and industry bias can obstruct the disclosure of relevant adverse reactions [6, [8] [9] [10] [11] [12] [13] [14] . Therefore, fundamental evidence regarding drug safety data appears to be routinely missing from drug inserts that are a main information source relied upon by healthcare providers [1, 15, 16] .
Accordingly, the analysis of real-world, post-approval safety data appears vital to comprehensively assess a drug's true safety profile. US FDA collects post-marketing AE data in the FDA Adverse Event Reporting System (FAERS) [17] . FDA uses these data internally to issue safety warnings, update drug information labels, and restrict the use of or remove medications from the market. The use of these data by broader groups within the healthcare community is a growing trend.
The probability that an AE-drug pair may be a relevant safety issue can either be derived expertly or by data-driven techniques. One data approach involves the use of disproportional reporting methods that measure observed versus 'expected' reporting rates of AE-drug pairs. This technique has been successfully applied to the analysis of post-marketing AE reporting databases such as FAERS [17] , EudraVigilance [18] , and VigiBase [19] .
A shortcoming of disproportionality methods is that they are typically calculated for a single drug-AE pair. With more than 30 million drug-AE pairs in the FAERS database alone, the issue of what to focus on is formidable. Most drug-AE pairs are not serious, possibly related to an underlying disease or condition or of little real-world concern.
Therefore, two key issues for developing a pertinent drug-AE signaling platform are (1) being able to properly identify AEs of interest and (2) using a disproportional reporting method that balances the need for broad signal detection thresholds with acceptable false-positive rates.
Our approach was to use FAERS data in conjunction with AE types that had a demonstrated interest to FDA because they had been subject to past regulatory action. Our goal was to develop a model that could significantly reduce the number of potential drug-AE signals of interest and also reliably predict individual drug label changes.
Methods

FDA Adverse Event Reporting System (FAERS) Data Processing
Publically available FAERS ASCII data files were downloaded from FDA's website [20] , and then each raw FAERS 
[21] AE terms. Case reports that were missing or contained malformed key identification fields were discarded. As long as the aforementioned fields were contained in a given case report, allowable missing data included age, gender, weight, outcome, and condition. Cases were discarded if the drug name was found to be indeterminate.
Drug name text mapping was accomplished as previously described [22] . Multiple names for the same drug were normalized into a single brand name. National Drug File Reference Terminology [23] was used to provide ancillary information on class and mechanism of action. In brief, for each case report, drug names, route of administration and dose form were matched to pre-existing, manually verified mappings stored in the 'Reference Set.' Cases that matched stored results in the Reference Set were automatically mapped to the appropriate brand name. The automated matching process then utilized a combination of fuzzy string matching, string distance, and phonetic matching algorithms to correct for drug name misspellings and incorrect data within major fields (i.e., removal of non-alphanumeric characters, whitespaces, line breaks, and the inclusion of dosages or routes of administration as part of the drug name field). For automated matching, we used processes described by Peters et al. [24] with modifications including utilization of Dice's coefficient instead of Jaccard's coefficient as the string similarity metric, and additional pre-classifications of drug names based on the presence of key features: route of administration, salt name(s), multiple ingredients, and dose form. The feature-based preclassification step was used to optimize subset selection of the reference drug set for a given input string.
Case reports left unmapped after automated matching procedures were manually processed and assigned to specific brand names by a team of analysts. These manually verified assignments were then added back to the Reference Set. Duplicate case reports were removed by using the earliest Individual Case Safety Report (ICSR) for the same patient ID number in the same calendar year. Figure 1 is a visual representation of the methods.
Removal of Disease-Related Adverse Events (AEs)
For each drug-AE pair, we cross checked the AE with the approved indications listed in that drug's prescribing information. If the medical and clinical literature indicated that the AE could be related to the underlying disease or disorder, we labeled that AE disease related and removed it from our analysis.
AE Coding
AE information was coded according to MedDRA Ò version 18.0 [21] . 'Primary suspect' designations in FAERS case reports were quantified in an attempt to restrict the analysis to those drugs directly suspected of causing the AE. A discrepancy occasionally observed with FAERS case reports is that disease-related symptoms are sometimes listed in the 'adverse event' field. In instances where such mistakes were easily identified, we excluded those 'AEs' from analysis.
Disproportionality Analysis
Data-mining algorithms based on disproportionality can be used to estimate the relative frequency of AE reporting associated with the use of a specific drug. The Reporting Odds Ratio (ROR) is a disproportionality measure commonly used by drug safety professionals to help identify drug-AE pairs that are reported more frequently than expected. The method compares expected AE reporting frequencies (based upon all drugs and all AEs in the FAERS database) with the amounts reported for a given drug. An ROR score [1.0 indicates that there is a higher than expected reporting rate for a given drug-AE combination. We derived ROR by the use of standard formulas [25] .
Minimum Cases for Inclusion
If a drug-AE combination had between two and five cases, it was deemed to be an active signal if the ROR had a lower 95 % confidence interval [2.0.
Construction of the Eligible Signal AE list
The signal-eligible AE list was made by (1) identifying 165 Important Medical Event (IME) term serious [26] AEs from 427 FDA Drug Safety Communications [27] issued from January 2008 to March 2014; (2) adding 79 FDA Designated Medical Event (DME) [28] AEs; and (3) adding select IME serious AEs from 1232 FDA drug safety labeling changes [29] issued from January 2008 to July 2015. These processes were limited to AEs and therefore did not consider specific drugs. Changes that detailed AEs that were already listed on a given drug's label (i.e. instances where the change constituted a clarification on earlier guidance or detailed an AE move from one section of a label to another) were not included. We also eliminated any labeling changes that were based entirely on data derived from clinical trials, animal studies, or class-wide changes based on another drug's FAERS-based label change. These processes added an additional 350 AEs to the signal eligible list, for a total of 594 eligible AEs. 
Different Inclusion Criteria for Three Especially Serious AEs
Three DME AEs are so closely watched by FDA that we lowered the primary suspect count minimum to just one case, with no ROR minimum, to generate an active signal. These 'especially serious' AEs were progressive multifocal leukoencephalopathy (PML), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN).
Training Group of Drugs to Find AEs Not Typically Acted On by FDA
We selected a training group of 109 drugs that each had been subjected to at least one FDA mandated label change from 2008 to 2015. We mined all historical labels for each of these drugs to determine exact label change dates. This group was used to determine which AEs were most likely to result in false signals (a measure of how often a signal was triggered but did not end up on a given drug's label).
AEs that had a minimum of three false signals and an overall label change success rate of B25 % were excluded from the signal eligible list. A total of 45 AEs were excluded based on this process. The top ten excluded AEs were multi-organ failure, cholestasis, hepatocellular injury, coma, hypothermia, tubulointerstitial nephritis, maternal drugs affecting foetus, pneumonia aspiration, circulatory collapse, and encephalitis (please see supplemental Table 1 for a list of all 45). After these 45 were removed, the total eligible AE list was reduced to 549.
Testing Group of Drugs to Determine Signaling Accuracy
A test group of 29 drugs was selected because they each had been subjected to at least one FDA mandated label change from 2008 to 2015 and each was approved from 2005 to 2010. Accordingly, they were relatively current medications and had also been on the market long enough to have produced numerous true and false signals. None of the 29 test drugs were included in the construction of the signal eligible list or the training processes described above. Using the final signal eligible list of 549 AEs, we analyzed the test group of 29 drugs for successful and unsuccessful signal rates (percentage of time that a given drug-AE combination was put on a label by FDA action within 5 years after the signaling date) ( Tables 1, 2, 3) . We also quantified the number of times the model predicted at least one AE-drug pair for each labeling change for each drug (Table 4) . Finally, we measured the recall rate for all drug-AE pairs added to labels. For a visual representation of the method please see Fig. 2 .
Results
The exclusion and inclusion criteria for relevant FDA actions and AEs resulted in the designation of just 97 drug-AE pairs as eligible signals. As of July 2015, this group of 29 drugs had 41,834 potential drug-AE pairings. Therefore, the 97 signals signified a substantial focus because they represented just 0.23 % of potential drug-AE pairs for this group of medications. Over the time period examined, 71 label changes, containing 168 AEs, were issued for the group of 29 test drugs. Table 1 shows that on a per-drug basis, 73.21 % of signaled AE-drug pairs were added to their corresponding drug labels within 5 years after the signal trigger date. Table 2 lists the successful (within 5 years after the trigger date) signals in detail, with trigger date, trigger ROR values, and label added dates. Table 3 lists the unsuccessful (within 5 years after the trigger date) signals in detail, with trigger date and ROR values. Table 4 shows that for all FDA alerts that met our inclusion criteria, the system correctly identified one or more drug-AE parings in 47 of 71 future alerts (66 %) for the 29 drugs. The recall rate was 111 signaled AE-drug pairs added to their respective drug labels out of a possible 287 AE-drug pair changes for the 29 drugs.
Discussion
Much of the public and many healthcare providers assume that a given medication is safe because a regulatory body such as FDA approved it. History and post-marketing experiences have seriously challenged such assumed safety. Pre-approval clinical trials simply cannot be large, long, or varied enough to provide a comprehensive picture of a drug's safety profile; yet, it is precisely these incomplete results that form the majority of safety information contained in drug label inserts. AEs associated with the real-world use of approved drugs impact patient safety as well as downstream medical costs. Approximately 1,500,000 new annual AE case reports are now submitted to FDA alone, and there are millions of possible drug-AE pairs to track. This represents an obvious challenge on how best to provide focus regarding emerging drug issues.
Therefore, we used FDA's repository of post-marketing AEs (FAERS) to analyze side effects that had a historical demonstrated interest to FDA. We developed a set of rules to construct an eligible AE signal list that could be used to significantly reduce the number of potential drug-AE signals of interest. By using independent training and testing While the use of disproportional reporting methods has successfully been used by many before us to obtain signals of interest from AE databases such as FAERS [30] [31] [32] [33] [34] [35] [36] [37] , we know of no other previous effort that comprehensively focused on prior regulatory actions to drive inclusion and exclusion criteria for signaling.
In summary, by focusing on AE types that already had a demonstrated interest to FDA, we were able to construct a signaling system that could be used to highlight drug-AE pairs in FAERS data that might result in future regulatory action.
We suggest that such a focus on historical regulatory actions may increase the utility of signaling systems. We are encouraged that this method appears to offer both a way to focus on drug-AE pairs of particular interest and to provide suitable accuracy with regard to the issuance of FDA labeling changes. Future work will test these methods by using additional drugs, analytical reporting methods, and FDA labeling change data.
Limitations
While we limited this investigation to 'primary suspect' case reports in an attempt to restrict the analysis to those drugs directly suspected of causing a given AE, potential interactions with other drugs were not considered.
The group of training and/or test drugs may not have been representative of typical drugs, for reasons unknown to us, and therefore may not accurately represent the much broader group of all FDA-approved drugs.
The minimum case counts and ROR confidence interval limitations and/or the inclusion and exclusion criteria regarding eligible AEs and FDA alerts may have eliminated important regulatory actions from our analysis.
The choice of the ROR as a disproportional reporting measure may have affected inclusion and exclusion criteria, false positives, and success rates in materially different ways than what would have been obtained by using alternative methods such as the Bayes multi-item gamma Poisson shrinker, proportional reporting ratio, the Poisson- Dirichlet process, or the information component, for example [30] [31] [32] [33] [34] [35] [36] [37] . Comparing the ROR method against such other techniques was outside the scope of this analysis. Eligible AEs were largely selected because FDA subjected them to past action. Accordingly, AEs that have never been subject to FDA regulatory action might be missed with this system.
Given the breadth of systems that prescription drugs can affect, some of the AEs analyzed here might be associated with the disease itself and perhaps not directly caused by the administered drug(s). While we were careful to attempt to omit all 'disease-related' AEs from analysis, it cannot be stated that our methods excluded all of them. Alternatively, the removal of disease-related AEs may mask instances where drugs lead to exacerbations of underlying disease.
In general, post-marketing data may be subject to underreporting, reporting bias, masking, and confounding by comorbidities. An AE report does not definitively ascertain causality. For additional reviews regarding limitations associated with FAERS, please see Edwards et al. [38] , Tatonetti et al. [39] , and Auerbach and Kane [40] .
Conclusion
The methods disclosed here enabled a focus on only 0.23 % of potential drug-AE signals for a test group of drugs. Of those pairs, 73 % of triggered signals were added to their corresponding drug's label. In addition, 66 % of eligible FDA label changes listed one or more drug-AE pairs that the method signaled for. Accordingly, this appears to be an approach that can provide both focus, with regard to the vast number of potential drug-AE pairings, and a signal accuracy that may be useful for pharmacovigilance programs.
Future work will incorporate the analysis of additional label changes, a larger selection of drugs, inclusion of other Fig. 2 Visual representation of the inclusion and exclusion criteria for eligible signals. AE adverse event, PML progressive multifocal leukoencephalopathy, PS primary suspect, ROR reporting odds ratio, SJS Stevens-Johnson syndrome, TEN toxic epidermal necrolysis disproportional reporting methodologies, and an exploration of those AEs that were not successfully signaled for.
